Dr. Stavros Melemenidis | Nanotheranostics Awards | Best Researcher Award

Dr. Stavros Melemenidis | Nanotheranostics Awards | Best Researcher Award

Dr. Stavros Melemenidis , Stanford University School of Medicine , United States

Stavros Melemenidis, DPhil, is a distinguished figure in the field of Radiation Oncology, currently serving as Director of Pre-clinical Radiotherapy and Research Scientist at Stanford University’s Department of Radiation Oncology in Stanford, CA, USA. He completed his DPhil in Radiation Biology at the University of Oxford, where his research focused on molecular targeted imaging methods for lung metastasis and angiogenesis detection. Dr. Melemenidis holds a diverse educational background including degrees from UCLA and the University of Liverpool. His expertise spans preclinical radiotherapy, ultra-high dose-rate irradiation experiments, and the development of advanced imaging probes and animal models for cancer research. Dr. Melemenidis is recognized for his contributions to radiation therapy and imaging sciences, employing innovative techniques to advance cancer treatment and research.

Professional Profile:

Scopus

šŸŽ“Education:

Stavros Melemenidis, DPhil, has pursued an extensive educational journey encompassing a diverse array of disciplines. He earned his DPhil in Radiation Biology from the University of Oxford, UK, focusing on the development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis. His academic credentials also include a Cert. in Medical Physics from UCLA, USA, an M.Sc. in Radiation Biology from the University of Oxford, UK, and an M.Sc. in Radiometrics; Instrumentation and Modelling from the University of Liverpool, UK. Dr. Melemenidis began his academic path with a B.Sc. in Physics: Medical Applications from the University of Liverpool and an A.Eng. in PC Systems and Peripheral Equipment from IIEK Neapoleos, Technical College, Greece. This diverse educational background has equipped him with expertise spanning radiation biology, medical physics, instrumentation, and modelling, contributing significantly to his research and leadership roles in the field of Radiation Oncology at Stanford University.

šŸ¢Work Experience:

Stavros Melemenidis, DPhil, holds key positions in the field of Radiation Oncology at Stanford University in Stanford, CA, USA. Since January 2023, he has served as the Director of Pre-clinical Radiotherapy within the Department of Radiation Oncology, overseeing advanced research initiatives. Prior to this role, Dr. Melemenidis has been integral to the Division of Radiation Therapy as a Research Scientist since February 2020, contributing to innovative studies in radiation oncology. His earlier career includes impactful roles as a Postdoctoral Fellow at Stanford University from February 2016 to June 2020, where he focused on developing in vivo mouse tumor models and integrating imaging techniques with radiotherapy and immunotherapy. Previously, he was a Postdoctoral Fellow at the University of Oxford’s Department of Radiation Oncology from January 2015 to September 2015, conducting research on novel imaging probes for metastasis and angiogenesis detection. These experiences underscore Dr. Melemenidis’s dedication to advancing preclinical and clinical applications in radiation oncology through pioneering research and leadership.

Publication Top Notes:

  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation
    • Authors: Klett, K.C., Martin-Villa, B.C., Villarreal, V.S., Loo Jr, B.W., Heilshorn, S.C.
    • Citations: 1
  • Real-time optical oximetry during FLASH radiotherapy using a phosphorescent nanoprobe
    • Authors: Ha, B., Liang, K., Liu, C., Loo, B.W., Pratx, G.
    • Citations: 4
  • Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension
    • Authors: Taylor, S., Isobe, S., Cao, A., Snyder, M.P., Rabinovitch, M.
    • Citations: 10
  • Design and validation of a dosimetric comparison scheme tailored for ultra-high dose-rate electron beams to support multicenter FLASH preclinical studies
    • Authors: Jorge, P.G., Melemenidis, S., Grilj, V., Loo, B.W., Bailat, C.
    • Citations: 9

 

 

Nanotheranostics

Introduction of Nanotheranostics

Nanotheranostics research is a cutting-edge field at the intersection of nanotechnology, diagnostics, and therapy. It focuses on the development of multifunctional nanoparticles that can simultaneously diagnose and treat various diseases, revolutionizing the way we approach healthcare. By combining diagnostics and therapeutics into a single platform, nanotheranostics offers personalized, efficient, and precise medical interventions.

Cancer Theranostics šŸ©ŗ:

Explore how nanoparticles can be designed to target and treat cancer cells while providing real-time diagnostic information, enabling early detection and tailored treatments.

Cardiovascular Nanotheranostics ā¤ļø:

Investigate the use of nanosystems to diagnose and manage cardiovascular diseases, such as atherosclerosis and thrombosis, through targeted drug delivery and imaging.

Neurological Disorders šŸ§ :

Delve into nanotheranostic approaches for neurodegenerative diseases like Alzheimer’s and Parkinson’s, enabling early diagnosis and precise drug delivery to the brain.

Infectious Disease Detection and Treatment šŸ¦ :

Explore how nanotheranostics can play a vital role in diagnosing and combating infectious diseases, including rapid detection and targeted therapy delivery.

Theranostics in Regenerative Medicine šŸŒ±:

Examine how nanomaterials can aid in tissue engineering and regenerative therapies by simultaneously monitoring tissue regeneration progress and delivering growth factors or stem cells.